231 related articles for article (PubMed ID: 16269461)
1. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5.
Kitajima Y; Endo T; Nagasawa K; Manase K; Honnma H; Baba T; Hayashi T; Chiba H; Sawada N; Saito T
Endocrinology; 2006 Feb; 147(2):694-9. PubMed ID: 16269461
[TBL] [Abstract][Full Text] [Related]
2. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome.
Scotti L; Irusta G; Abramovich D; Tesone M; Parborell F
Mol Cell Endocrinol; 2011 Mar; 335(2):116-25. PubMed ID: 21238536
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats.
Kitajima Y; Endo T; Manase K; Nishikawa A; Shibuya M; Kudo R
Fertil Steril; 2004 Mar; 81 Suppl 1():842-9. PubMed ID: 15019818
[TBL] [Abstract][Full Text] [Related]
4. In vivo intrabursal administration of bioactive lipid sphingosine-1-phosphate enhances vascular integrity in a rat model of ovarian hyperstimulation syndrome.
Di Pietro M; Pascuali N; Scotti L; Irusta G; Bas D; May M; Tesone M; Abramovich D; Parborell F
Mol Hum Reprod; 2017 Jun; 23(6):417-427. PubMed ID: 28379469
[TBL] [Abstract][Full Text] [Related]
5. Effects of gonadotropin-releasing hormone antagonists on the expression of vascular endothelial growth factor and its receptors in a rat model of ovarian hyperstimulation syndrome.
Tong XM; Zhang SY; Song T; Xu WH; Lin XN; Shu J; Liu L
Chin Med J (Engl); 2008 Dec; 121(23):2434-9. PubMed ID: 19102964
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade.
Gómez R; Simón C; Remohí J; Pellicer A
Endocrinology; 2002 Nov; 143(11):4339-48. PubMed ID: 12399430
[TBL] [Abstract][Full Text] [Related]
7. Prevention of the onset of ovarian hyperstimulation syndrome (OHSS) in the rat after ovulation induction with a low molecular weight agonist of the LH receptor compared with hCG and rec-LH.
van de Lagemaat R; Raafs BC; van Koppen C; Timmers CM; Mulders SM; Hanssen RG
Endocrinology; 2011 Nov; 152(11):4350-7. PubMed ID: 21896671
[TBL] [Abstract][Full Text] [Related]
8. Administration of low-dose LH induces ovulation and prevents vascular hyperpermeability and vascular endothelial growth factor expression in superovulated rats.
Gómez R; Lima I; Simón C; Pellicer A
Reproduction; 2004 Apr; 127(4):483-9. PubMed ID: 15047939
[TBL] [Abstract][Full Text] [Related]
9. A potential novel strategy, inhibition of vasopressin-induced VEGF secretion by relcovaptan, for decreasing the incidence of ovarian hyperstimulation syndrome in the hyperstimulated rat model.
Cenksoy C; Cenksoy PO; Erdem O; Sancak B; Gursoy R
Eur J Obstet Gynecol Reprod Biol; 2014 Mar; 174():86-90. PubMed ID: 24405730
[TBL] [Abstract][Full Text] [Related]
10. GnRH Agonist Triggering Modulates PEDF to VEGF Ratio Inversely to hCG in Granulosa Cells.
Miller I; Chuderland D; Ron-El R; Shalgi R; Ben-Ami I
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1428-36. PubMed ID: 26308290
[TBL] [Abstract][Full Text] [Related]
11. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability.
Gómez R; Simón C; Remohí J; Pellicer A
Biol Reprod; 2003 Jun; 68(6):2164-71. PubMed ID: 12606463
[TBL] [Abstract][Full Text] [Related]
12. Molecular mechanisms of ovarian hyperstimulation syndrome: paracrine reduction of endothelial claudin 5 by hCG in vitro is associated with increased endothelial permeability.
Rodewald M; Herr D; Duncan WC; Fraser HM; Hack G; Konrad R; Gagsteiger F; Kreienberg R; Wulff C
Hum Reprod; 2009 May; 24(5):1191-9. PubMed ID: 19168871
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the effects of letrozole and cabergoline on vascular permeability, ovarian diameter, ovarian tissue VEGF levels, and blood PEDF levels, in a rat model of ovarian hyperstimulation syndrome.
Şahin N; Apaydın N; Töz E; Sivrikoz ON; Genç M; Turan GA; Cengiz H; Eskicioğlu F
Arch Gynecol Obstet; 2016 May; 293(5):1101-6. PubMed ID: 26690356
[TBL] [Abstract][Full Text] [Related]
14. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
Hsieh YY; Chang CC; Tsai HD
Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
[TBL] [Abstract][Full Text] [Related]
15. Comparison of "triggers" using leuprolide acetate alone or in combination with low-dose human chorionic gonadotropin.
Shapiro BS; Daneshmand ST; Garner FC; Aguirre M; Hudson C
Fertil Steril; 2011 Jun; 95(8):2715-7. PubMed ID: 21550042
[TBL] [Abstract][Full Text] [Related]
16. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model.
Gomez R; Gonzalez-Izquierdo M; Zimmermann RC; Novella-Maestre E; Alonso-Muriel I; Sanchez-Criado J; Remohi J; Simon C; Pellicer A
Endocrinology; 2006 Nov; 147(11):5400-11. PubMed ID: 16901966
[TBL] [Abstract][Full Text] [Related]
17. Everolimus, an mTOR pathway inhibitor, is highly successful on ovarian hyperstimulation syndrome by reducing ovarian weight and progesterone levels: a preclinical experimental randomized controlled study.
Kosmas IP; Kitsou C; Lazaros L; Markoula S; Peschos D; Mynbaev O; Tournaye H; Prapas N; Prapas I; Zikopoulos A; Galani V; Georgiou I
Gynecol Endocrinol; 2015; 31(9):702-7. PubMed ID: 26172931
[TBL] [Abstract][Full Text] [Related]
18. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome.
Rizk B; Aboulghar M; Smitz J; Ron-El R
Hum Reprod Update; 1997; 3(3):255-66. PubMed ID: 9322101
[TBL] [Abstract][Full Text] [Related]
19. Effect of GnRH agonist and hCG treatment on VEGF, angiopoietin-2, and VE-cadherin: trying to explain the link to ovarian hyperstimulation syndrome.
Cerrillo M; Pacheco A; Rodríguez S; Gómez R; Delgado F; Pellicer A; Garcia-Velasco JA
Fertil Steril; 2011 Jun; 95(8):2517-9. PubMed ID: 21269615
[TBL] [Abstract][Full Text] [Related]
20. Organ-specific production control of vascular endothelial growth factor in ovarian hyperstimulation syndrome-model rats.
Ishikawa K; Ohba T; Tanaka N; Iqbal M; Okamura Y; Okamura H
Endocr J; 2003 Oct; 50(5):515-25. PubMed ID: 14614207
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
